Johnson & Johnson makes executive appointments
Furthers succession plans to ensure sustainable future
‘These appointments will ensure we are well-positioned for sustainable growth into the future,’ said Weldon. ‘The changes are an appropriate step in furthering our long-term succession plans, and assuring talented, experienced leaders at all levels of the organisation.’
Gorsky will assume expanded responsibilities that include the medical device and diagnostics group, global supply chain, government affairs and policy and the Johnson & Johnson development corporation.
McCoy expands her role to include the pharmaceuticals group, consumer group, the corporate office of science and technology and corporate affairs.
Meanwhile, Michael Mahoney, currently company group chairman of DePuy, is named worldwide chairman, MD&D, and will report to Gorsky.
Jesse Wu, currently company group chairman, Global Markets Organisation, Consumer, will take the role of worldwide chairman, Consumer, and will report to McCoy.
Joaquin Duato, formerly pharmaceuticals company group chairman, Americas, is named worldwide chairman, pharmaceuticals, with responsibility for commercial businesses and operations. Appointed as company group chairman for North America in March 2009, Duato assumed additional responsibility for Latin America earlier this year.
Paul Stoffels, currently global head of pharmaceuticals research and development is named worldwide chairman, pharmaceuticals, with responsibility for research and development, business and strategic development.
Finally, Peter Fasolo, worldwide vice president, human resources, will join the executive committee and continue to focus on talent development and succession planning at all levels across the corporation.
Weldon said: ‘These leadership changes are designed to ensure that our company remains well-positioned and appropriately structured for sustainable, long-term growth in the healthcare industry.’
You may also like
Media
Only a handful of pharma companies are developing the urgently needed new medicines for the poor
The development of new medical products that are considered the highest priority for people in developing countries is highly concentrated – among five pharmaceutical companies and on five diseases
